tbuckley/cabot-search huggingface dataset:
Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta‐analysis
Authors: Sonali Paul, Aaron Dickstein, Akriti Saxena, Norma Terrin, Kathleen Viveiros, Ethan M. Balk, John B. Wong
Journal: Hepatology (2017)

Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation. Because of conflicting studies about whether the antibody to hepatitis B surface antigen (anti‐HBs) protects against reactivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hematological malignancies, we conducted a meta‐analysis to determine if anti‐HBs reduces HBV reactivation risk. We sought English‐language studies through March 1, 2016, in Medline and other sources that examined reactivation in patients with resolved HBV infection receiving chemotherapy for hematologic malignancies. The absolute risks and odds ratio (OR) of reactivation with versus without anti‐HBs were estimated in random‐effects model meta‐analyses. In 20 studies involving 1,672 patients not receiving antiviral prophylaxis, the reactivation risk was 14% (95% confidence interval [CI] 9.4%‐19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%‐7.0%) in 1,284 patients who also had anti‐HBs. Anti‐HBs reduced reactivation risk with a pooled OR of 0.21 (95% CI 0.14‐0.32) versus patients with antibody to hepatitis B core antigen only. Similar results were found when limiting the analysis to rituximab chemotherapy (OR = 0.19, 95% CI 0.11‐0.32) and lymphoma (OR = 0.18, 95% CI 0.11‐0.28). Conclusion : In patients with resolved HBV receiving chemotherapy for hematological malignancies without antiviral prophylaxis, anti‐HBs positivity is associated with a decreased risk of reactivation; HBV screening in this patient population should include the routine use of anti‐HBs, and those who are anti‐HBs‐negative should receive antiviral prophylaxis. Future studies should examine the effect of anti‐HBs serum titers, the potential role for booster vaccinations, and antiviral prophylaxis prior to chemotherapy in this patient population. (H epatology 2017;66:379–388).
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Authors: Padmanee Sharma, Margitta Retz, Arlene Siefker-Radtke, Ari Baron, Andrea Necchi, Jens Bedke, Elizabeth R Plimack, Daniel Vaena, Marc-Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta Pal, Chikara Ohyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D Galsky
Journal: The Lancet Oncology (2017)
Successful Haploidentical Hematopoietic Cell Engraftment Using a Non-Myeloablative Preparative Regimen Including Natural Killer (NK) Cells
Authors: Sarah Cooley, Purvi Gada, David McKenna, Valarie McCullar, Susan Fautsch, Michael Verneris, Bruce R Blazar, Linda J Burns, Philip B McGlave, Daniel J. Weisdorf, Jeffrey S Miller
Journal: Blood (2008)
Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data
Authors: Saravanan Ganesan, Ezhilarasi Chendamarai, Jayandharan G Rao, Sangeetha Hareendran, Ansu Abu Alex, Rayaz Ahmed, Aby Abraham, Auro Viswabandhya, Biju George, Alok Srivastava, Vikram Mathews
Journal: Blood (2011)
Biodegradable scaffolds promote tissue remodeling and functional improvement in non-human primates with acute spinal cord injury
Authors: Jonathan R. Slotkin, Christopher D. Pritchard, Brian Luque, Janice Ye, Richard T. Layer, Mathew S. Lawrence, Timothy M. O'Shea, Roland R. Roy, Hui Zhong, Isabel Vollenweider, V. Reggie Edgerton, Grégoire Courtine, Eric J. Woodard, Robert Langer
Journal: Biomaterials (2017)
Clonality and Phenotype in Spleens From Patients with Primary Immune Thrombocytopenia,
Authors: Elena Sabattini, Pier Paolo Piccaluga, Claudia Mannu, Anna Candoni, Anna Gazzola, Carlo Sagramoso, Eleonora Toffoletti, Nicola Vianelli, Nicola Polverelli, Stefano Pileri, Carla Di Loreto, Stefano Pizzolitto, Francesco Zaja
Journal: Blood (2011)
Proteomic Analysis of Post Transplant Lymphoproliferative Disorders (PTLD) Using Nanoscale Protein Microarray Techniques.
Authors: Yazan Alsayed, Alexey Leontovich, Michael Timm, Mona Melhem, Michael Nalesnik, Diane George, Ujjal Singha, Alissa Huston, Lanie Francis, Suzanne Lentzsch, G. David Roodman, Ronald Herberman, Irene M. Ghobrial
Journal: Blood (2005)
Correlation of high levels of immature blood vessels in colorectal tumors with longer survival following bevacizumab treatment.
Authors: S. Noonan, P. Martin, M. Biniecka, A. Maguire, M. Tosetto, J. Hyland, K. Sheahan, D. O'Donoghue, H. Mulcahy, D. Fennelly, J. O'Sullivan
Journal: Journal of Clinical Oncology (2011)

10586 Background: Bevacizumab improves overall survival in metastatic colorectal cancer patients. Bevacizumab is a first line treatment in all metastatic colorectal cancer patients, however only 38-44% respond. Currently, there is no good marker to depict treatment response. Tumour microvascular density has been shown be a prognostic factor in late stage colorectal cancer patients, however, it does not predict response. Blood vessels mature by the recruitment of pericytes. We hypothesise blood vessels that lack pericytes will be more susceptible to regression and these tumours may benefit from targeting with bevacizumab. Methods: 80 patients had a primary colorectal cancer resection and were subsequently treated with bevacizumab in our tertiary referral centre of excellence. Tumours were stained using dual immunofluorescence staining for factor VIII (an endothelial marker) and α-smooth muscle actin (a pericyte marker). Levels of immature and mature blood vessels were screened using fluorescent microscopy, scoring multiple fields of view. The mean levels of immature and mature blood vessels were scored and correlated with overall and progression free survival using Spearman correlations and multivariate analyses. Results: 37 patients were metastatic at diagnosis and 43 were initially Duke’s A, B or C at diagnosis (early stage) and subsequently developed metastases. Mean duration on bevacizumab was 10.6 months. Mean overall survival was 38.6 months. Interestingly, there was no difference between levels of immature and mature vessels in tumours of early stage patients and metastatic patients. Patients with higher levels of immature blood vessels had longer survival following treatment (p value = 0.026). This remained significant following multivariate analyses correcting for gender, stage at diagnosis, whether patients received chemotherapy before or after treatment with bevacizumab and whether or not bevacizumab was first line or not. Conclusions: We have shown for the first time that the maturity levels of blood vessels in tumours significantly correlates to survival following treatment with bevacizumab.
MEF2B Mutations Lead to De-Regulated Expression of the BCL6 Oncogene in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Authors: Carol Y Ying, David Dominguez-Sola, Melissa Fabi, Ivo C Lorenz, Mukesh Bansal, Andrea Califano, Laura Pasqualucci, Katia Basso, Riccardo Dalla-Favera
Journal: Blood (2012)
A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia
Authors: Tapan Kadia, Maria L Delioukina, Hagop M. Kantarjian, Michael J Keating, William G. Wierda, Jan A. Burger, Scott Wieland, Daniel Levitt
Journal: Blood (2011)
Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopath
Authors: Jennifer Yui, Roshini S Abraham, Dong Chen, Fernando Fervenza, Ronald S. Go, Sanjeev Sethi, Cheryl Tran, Jeffrey L. Winters, Hatem Amer, Aneel A. Ashrani, Carl Cramer, Michelle Ann Elliott, Vesna Garovic, William J Hogan, C Christopher Hook, Elizabeth Lorenz, David L Murray, Juliana Perez Botero, Rajiv K. Pruthi, Wendy White, Maria Alice V Willrich, Nelson Leung
Journal: Blood (2015)
Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre
Authors: Maximilien Grall, Elie Azoulay, Lionel Galicier, François Provôt, Alain Wynckel, Pascale Poullin, Steven Grange, Jean‐Michel Halimi, Alexandre Lautrette, Yahsou Delmas, Claire Presne, Mohamed Hamidou, Stéphane Girault, Frédéric Pène, Pierre Perez, Tarik Kanouni, Amélie Seguin, Christiane Mousson, Dominique Chauveau, Mario Ojeda‐Uribe, Virginie Barbay, Agnès Veyradier, Paul Coppo, Ygal Benhamou
Journal: American Journal of Hematology (2017)

Thrombotic thrombocytopenic purpura (TTP) has a devastating prognosis without adapted management. Sources of misdiagnosis need to be identified to avoid delayed treatment. We studied 84 patients with a final diagnosis of severe (<10%) acquired ADAMTS13 deficiency-associated TTP from our National database that included 423 patients, who had an initial misdiagnosis (20% of all TTP). Main diagnostic errors were attributed to autoimmune thrombocytopenia, associated (51%) or not (37%) with autoimmune hemolytic anemia. At admission, misdiagnosed patients were more frequently females (P = .034) with a history of autoimmune disorder (P = .017) and had organ involvement in 67% of cases; they had more frequently antinuclear antibodies (P = .035), a low/undetectable schistocyte count (P = .001), a less profound anemia (P = .008), and a positive direct antiglobulin test (DAT) (P = .008). In multivariate analysis, female gender (P = .022), hemoglobin level (P = .028), a positive DAT (P = .004), and a low schistocytes count on diagnosis (P < .001) were retained as risk factors of misdiagnosis. Platelet count recovery was significantly longer in the misdiagnosed group (P = .041) without consequence on mortality, exacerbation and relapse. However, patients in the misdiagnosed group had a less severe disease than those in the accurately diagnosed group, as evidenced by less organ involvement at TTP diagnosis (P = .006). TTP is frequently misdiagnosed with autoimmune cytopenias. A low schistocyte count and a positive DAT should not systematically rule out TTP, especially when associated with organ failure.
RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis
Authors: Kelsi Andrade, Jaime Fornetti, Ling Zhao, Scott C. Miller, R. Lor Randall, Neysi Anderson, Susan E. Waltz, Mark McHale, Alana L. Welm
Journal: Science Translational Medicine (2017)

Inhibition of RON kinase prevents pathogenic bone destruction in mouse models and in a first-in-human clinical study.
Multiple Clonal TCR Gene Rearrangements Are Typical in Peripheral T-Cell Lymphoma Not Otherwise Specified
Authors: Yulia V Sidorova, Natalia G. Chernova, Natalia V. Ryzhikova, Svetlana Yu. Smirnova, Yulia E Vinogradova, Alla M. Kovrigina, Eugene E. Zvonkov, Andrey B. Sudarikov, Elena N. Parovichnikova, Valeri G. Savchenko
Journal: Blood (2015)
Dietary Intakes of Eicosapentaenoic Acid and Docosahexaenoic Acid and Risk of Age-Related Macular Degeneration
Authors: Juan Wu, Eunyoung Cho, Edward L. Giovannucci, Bernard A. Rosner, Srinivas M. Sastry, Walter C. Willett, Debra A. Schaumberg
Journal: Ophthalmology (2017)
Transient Opening of the Mitochondrial Permeability Transition Pore Induces Microdomain Calcium Transients in Astrocyte Processes
Authors: Amit Agarwal, Pei-Hsun Wu, Ethan G. Hughes, Masahiro Fukaya, Max A. Tischfield, Abraham J. Langseth, Denis Wirtz, Dwight E. Bergles
Journal: Neuron (2017)
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections
Authors: Marcus Lind, William Polonsky, Irl B. Hirsch, Tim Heise, Jan Bolinder, Sofia Dahlqvist, Erik Schwarz, Arndís Finna Ólafsdóttir, Anders Frid, Hans Wedel, Elsa Ahlén, Thomas Nyström, Jarl Hellman
Journal: JAMA (2017)

<h3>Importance</h3> The majority of individuals with type 1 diabetes do not meet recommended glycemic targets. <h3>Objective</h3> To evaluate the effects of continuous glucose monitoring in adults with type 1 diabetes treated with multiple daily insulin injections. <h3>Design, Setting, and Participants</h3> Open-label crossover randomized clinical trial conducted in 15 diabetes outpatient clinics in Sweden between February 24, 2014, and June 1, 2016 that included 161 individuals with type 1 diabetes and hemoglobin A<sub>1c</sub>(HbA<sub>1c</sub>) of at least 7.5% (58 mmol/mol) treated with multiple daily insulin injections. <h3>Interventions</h3> Participants were randomized to receive treatment using a continuous glucose monitoring system or conventional treatment for 26 weeks, separated by a washout period of 17 weeks. <h3>Main Outcomes and Measures</h3> Difference in HbA<sub>1c</sub>between weeks 26 and 69 for the 2 treatments. Adverse events including severe hypoglycemia were also studied. <h3>Results</h3> Among 161 randomized participants, mean age was 43.7 years, 45.3% were women, and mean HbA<sub>1c</sub>was 8.6% (70 mmol/mol). A total of 142 participants had follow-up data in both treatment periods. Mean HbA<sub>1c</sub>was 7.92% (63 mmol/mol) during continuous glucose monitoring use and 8.35% (68 mmol/mol) during conventional treatment (mean difference, −0.43% [95% CI, −0.57% to −0.29%] or −4.7 [−6.3 to −3.1 mmol/mol];<i>P</i> &lt; .001). Of 19 secondary end points comprising psychosocial and various glycemic measures, 6 met the hierarchical testing criteria of statistical significance, favoring continuous glucose monitoring compared with conventional treatment. Five patients in the conventional treatment group and 1 patient in the continuous glucose monitoring group had severe hypoglycemia. During washout when patients used conventional therapy, 7 patients had severe hypoglycemia. <h3>Conclusions and Relevance</h3> Among patients with inadequately controlled type 1 diabetes treated with multiple daily insulin injections, the use of continuous glucose monitoring compared with conventional treatment for 26 weeks resulted in lower HbA<sub>1c</sub>. Further research is needed to assess clinical outcomes and longer-term adverse effects. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT02092051
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Authors: Matthew S. Davids, Andrew W. Roberts, John F. Seymour, John M. Pagel, Brad S. Kahl, William G. Wierda, Soham Puvvada, Thomas J. Kipps, Mary Ann Anderson, Ahmed Hamed Salem, Martin Dunbar, Ming Zhu, Franklin Peale, Jeremy A. Ross, Lori Gressick, Monali Desai, Su Young Kim, Maria Verdugo, Rod A. Humerickhouse, Gary B. Gordon, John F. Gerecitano
Journal: Journal of Clinical Oncology (2017)

Purpose B-cell leukemia/lymphoma-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes. A phase I trial in patients with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selective, potent, orally bioavailable BCL-2 inhibitor. Patients and Methods A total of 106 patients with relapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts. Treatment commenced with a 3-week dose ramp-up period for most patients in dose-escalation cohorts and for all patients in safety expansion. Results NHL subtypes included mantle cell lymphoma (MCL; n = 28), follicular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL arising from chronic lymphocytic leukemia (Richter transformation; n = 7), Waldenström macroglobulinemia (n = 4), and marginal zone lymphoma (n = 3). Venetoclax was generally well tolerated. Clinical tumor lysis syndrome was not observed, whereas laboratory tumor lysis syndrome was documented in three patients. Treatment-emergent adverse events were reported in 103 patients (97%), a majority of which were grade 1 to 2 in severity. Grade 3 to 4 events were reported in 59 patients (56%), and the most common were hematologic, including anemia (15%), neutropenia (11%), and thrombocytopenia (9%). Overall response rate was 44% (MCL, 75%; FL, 38%; DLBCL, 18%). Estimated median progression-free survival was 6 months (MCL, 14 months; FL, 11 months; DLBCL, 1 month). Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes. We determined 1,200 mg to be the recommended single-agent dose for future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable response in MCL. Additional investigations including combination therapy to augment response rates and durability are ongoing.
Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.
Authors: Christine Mayr, Cathrine Schulz, Stephan Stilgenbauer, Alexander Kröber, Hartmut Döhner, Ulrich Jäger, Birgit Kainz, Georg Hopfinger, Rüdiger Hoffmann, Clemens Wendtner, Michael Hallek, Michael R. Speicher
Journal: Blood (2006)
Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis
Authors: Moritz Peiseler, Tina Liebscher, Marcial Sebode, Roman Zenouzi, Johannes Hartl, Hanno Ehlken, Nadine Pannicke, Christina Weiler-Normann, Ansgar W. Lohse, Christoph Schramm
Journal: Clinical Gastroenterology and Hepatology (2017)
Reduction in Incidence of Severe Infections by Transplantation of High Doses of Haploidentical T Cells Selectively Depleted of Alloreactive Units
Authors: Denis-Claude Roy, Mireille Guerin, Radia Sidi Boumedine, Silvy Lachance, Sandra Cohen, Guy Sauvageau, Thomas Kiss, Lambert Busque, Jean Morin, Marie-Claude Guertin, Andrea Velardi, Katayoun Rezvani, Stephan Mielke, R. Maarten Egeler, A. John Barrett, Claude Perreault, Jean Roy
Journal: Blood (2011)
The Heart in Dystrophia Myotonica
Authors: Charles Fisch, Paul V. Evans
Journal: New England Journal of Medicine (1954)

IN a recent review1 of 85 cases of dystrophia myotonica in which electrocardiographic, roentgenographic or anatomic data, or all, were available it was found that most of the patients manifested changes suggestive or diagnostic of heart disease. Only a few cases were studied post mortem, and in most the description of the heart left much to be desired.2 3 4 5 6 7 Recently, we had the opportunity to study a patient with dystrophia myotonica who manifested atrial flutter and died of acute heart failure. The anatomic changes in the heart were striking and form the basis of this report.Case ReportW.D., a 41-year-old . . .
Red-State Medicaid Expansions — Achilles’ Heel of ACA Repeal?
Authors: Benjamin D. Sommers, Arnold M. Epstein
Journal: New England Journal of Medicine (2017)

Surveys of low-income adults in four Southern U.S. states show that Medicaid expansions have improved access to care, affordability, chronic disease management, and self-reported health. Attitudes toward the Affordable Care Act vary according to state Medicaid policies.
Patient body image, self-esteem, and cosmetic results of minimally invasive robotic cardiac surgery
Authors: Taner İyigün, Mehmet Kaya, Sevil Özgül Gülbeyaz, Nurhan Fıstıkçı, Gözde Uyanık, Bilge Yılmaz, Burak Onan, Korhan Erkanlı
Journal: International Journal of Surgery (2017)
A JAK2 Germline Genetic Variation Is Associated with Shortened Survival in Primary Myelofibrosis: Clinical and JAK2V617F Allele Burden Correlates of rs12343867 SNP Genotype in 132 Cases.
Authors: Ayalew Tefferi, Terra Lasho, Christy Finke, Kebede Hussein, Michelle Elliott, Animesh D. Pardanani
Journal: Blood (2009)
A Multicenter Clinicopathologic Experience of HTLV-1 ATLL: A Retrospective 15 Year Review Reveals Little Progress.
Authors: Adrienne A. Phillips, Iuliana Shapira, Robert D. Willim, Jasotha Sanmugarajah, William B. Solomon, Steven M. Horwitz, David G. Savage, Gerald Soff, Owen A. O’Connor
Journal: Blood (2007)
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
Authors: Dominik Glodzik, Sandro Morganella, Helen Davies, Peter T Simpson, Yilong Li, Xueqing Zou, Javier Diez-Perez, Johan Staaf, Ludmil B Alexandrov, Marcel Smid, Arie B Brinkman, Inga Hansine Rye, Hege Russnes, Keiran Raine, Colin A Purdie, Sunil R Lakhani, Alastair M Thompson, Ewan Birney, Hendrik G Stunnenberg, Marc J van de Vijver, John W M Martens, Anne-Lise Børresen-Dale, Andrea L Richardson, Gu Kong, Alain Viari, Douglas Easton, Gerard Evan, Peter J Campbell, Michael R Stratton, Serena Nik-Zainal
Journal: Nature Genetics (2017)
The mTOR Inhibitor RAD001 (Everolimus) Inhibits Myeloma Tumor Growth In Vivo and Enhances the Anti-MM Effects of Bortezomib and Arsenic Trioxide.
Authors: Richard A. Campbell, Eric Sanchez, Jeffrey Steinberg, Michael Share, Joseph Wang, Mingjie Li, Richard Leuchter, Haiming Chen, Dror Shalitin, Shen Pang, Jonathan Said, James R. Berenson
Journal: Blood (2007)
The CALM/AF10 Fusion: Molecular Analysis of the Fusion Transcripts in 13 Cases of AML and ALL; Gene Expression Profiling Reveals HOX Gene Deregulation.
Authors: Alexandre Krause, Alexander Kohlmann, Torsten Haferlach, Claudia Schoch, Susanne Schnittger, Cristina Mecucci, Wolfgang D. Ludwig, Stefan K. Bohlander
Journal: Blood (2004)
Methylation of the PTEN Promoter Leads to PTEN Inactivation in Multiple Myeloma
Authors: Giovanna Piras, Giuseppina Pala, Antonella Uras, Anna Calvisi, Maria Monne, Angelo D Palmas, Annalisa Noli, Marco Murineddu, Erika Mariane, Rosanna Asproni, Maria Antonietta Fancello, Attilio Gabbas
Journal: Blood (2008)
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Authors: Vincent Meininger, Angela Genge, Leonard H van den Berg, Wim Robberecht, Albert Ludolph, Adriano Chio, Seung H Kim, P Nigel Leigh, Matthew C Kiernan, Jeremy M Shefner, Claude Desnuelle, Karen E Morrison, Susanne Petri, Diane Boswell, Jane Temple, Rajat Mohindra, Matt Davies, Jonathan Bullman, Paul Rees, Arseniy Lavrov, Susanne Abdulla, Cathy Alsop, Francesca Barbieri, Stewart Bates, James D Berry, Stephan A Botez, Gaelle Bruneteau, Andrea Calvo, Rodrigo Refoios Camejo, William Camu, Deven Chauhan, Veronique Danel-Brunaud, Jerzy Daniluk, Annelot Dekker, Alain Destee, Matthew Devine, Stephen DeWall, Johannes Dorst, Giuseppe Fuda, Harutoshi Fujimura, Andreas Funke, Torsten Grehl, Julian Grosskreutz, Usha Gungabissoon, Robert Henderson, Peggy Ho, William Huynh, Saiju Jacob, Raul Juntas-Morales, Byung-Jo Kim, Xenia Kobeleva, Sonja Koerner, Stephen Kolb, Katja Kollewe, Lawrence Korngut, Geraldine Lautrette, Amy Lee, Anthony Lynch, Rami Massie, Genevieve Matte, Darryl Menezes, Stefano Milleri, Linda Nichols, Kazutoshi Nishiyama, Mieko Ogino, Chris Parkinson, Pierre-François Pradat, Tino Prell, Jeffrey Price, Eleanor Ramsey, Thomas M Ringer, Kristiana Salmon, Christen Shoesmith, Marie Helene Soriani, Marloes Stam, Erik Steinberg, Rob Stubbs, Herman Sullivan, Philip Van Damme, Michael van Es, Anne Visser, Mary Lou Watson, Andrea Sylvia Winkler, Lorne Zinman, Margie Zoing
Journal: The Lancet Neurology (2017)
The Role of OX40 and Its Ligand in Acute Myeloid Leukemia: Expression, Function and Modulation of NK Cell Anti-Leukemia Reactivity
Authors: Carla E Schumacher, Tina Nuebling, Martin Hofmann, Benjamin J Schmiedel, Lothar Kanz, Gundram Jung, Helmut R Salih
Journal: Blood (2012)
CD69 and CXCR6 Identify a Distinct Population of Human Bone Marrow and Spleen Resident NK Cells
Authors: Gertjan Lugthart, Carly Vervat, Janine E Melsen, Monique M Van Ostaijen-ten Dam, Dave L Roelen, Maarten JD van Tol, Arjan C Lankester, Marco W Schilham
Journal: Blood (2015)